Accendra Health (ACH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
Annual Meeting scheduled for May 14, 2026, to be held virtually at 9:00 a.m. Eastern Time.
Shareholders of record as of March 18, 2026, are eligible to vote and attend.
Proxy materials, including the 2026 Proxy Statement and 2025 Annual Report, are available online.
Voting matters and shareholder proposals
Election of six directors for one-year terms and until successors are elected.
Ratification of KPMG LLP as independent auditor for the year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay).
Approval of the Amended and Restated 2023 Omnibus Incentive Plan.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Six nominees listed for election: Mark A. Beck, Gwendolyn M. Bingham, Kenneth Gardner-Smith, Stephen W. Klemash, Teresa L. Kline, Edward A. Pesicka.
Latest events from Accendra Health
- Q2 2026 featured a 10.1% revenue drop, major debt reduction, and CEO succession plans.ACH
Q2 2026 - Plans to raise up to $200 million via a flexible shelf offering for general corporate purposes.ACH
Registration filing - All proposals passed as the company advances its home-based care strategy nationwide.ACH
AGM 2026 - Q1 2026 revenue fell 6.8% to $627.8M, with a $1.5B balance sheet reset to boost liquidity.ACH
Q1 2026 - Shareholders to vote on directors, auditor, executive pay, and expanded equity plan amid strategic transformation.ACH
Proxy filing - 2026 guidance projects $2.55–$2.65B revenue, $335–$355M EBITDA, and strong cash flow.ACH
Q4 2025 - Q3 revenue up 5% to $2.7B, driven by Patient Direct and $198M debt reduction.ACH
Q3 2024 - Q2 revenue up 4–4.2% to $2.67–$2.7B; Rotech deal announced; 2024 outlook reaffirmed.ACH
Q2 2024 - $1.36B Rotech deal expands Patient Direct, targets $5B revenue, $50M synergies by year three.ACH
M&A Announcement